Pharmaceutical Product Monograph: Ketorolac Tromethamine Injection (30 mg/mL)
In the pharmaceutical industry, Ketorolac Tromethamine is a high-potency Non-Steroidal Anti-Inflammatory Drug (NSAID) of the pyrrolizine carboxylic acid group. As a pharmacist and manufacturer, I view this molecule as the “Non-Opioid Heavyweight”—it is technically designed to provide analgesic efficacy comparable to morphine or meperidine but without the respiratory depression or addiction potential associated with narcotics.
At your WHO-GMP facility in Mumbai, Ketorolac 30 mg/mL (1 mL or 2 mL ampoules) is a premium SKU for Surgery and Emergency Medicine portfolios. It is strictly a short-term intervention designed to bridge the gap between intense acute pain and recovery.
Therapeutic Profile: Primary Indications
Ketorolac injection is indicated for the short-term (up to 5 days) management of moderately severe acute pain that requires analgesia at the opioid level.
| Indication | Clinical Context | Technical Rationale |
| Post-Operative Pain | Major Surgery | Opioid Sparing: Used after abdominal, orthopedic, or gynecological surgery to reduce the requirement for morphine. |
| Renal Colic | Kidney Stones | Prostaglandin Inhibition: Reduces the intense ureteral pressure and inflammation caused by stones. |
| Acute Trauma | Emergency ER | Provides rapid relief for fractures or severe soft tissue injuries without clouding the patient’s consciousness. |
| Migraine (Severe) | Neurology | Often used in the ER as part of a “Migraine Cocktail” to terminate status migrainosus. |
Mechanism: Potent COX Inhibition
Ketorolac works by shutting down the “Pain Signaling Factory” in the peripheral tissues:
Enzyme Blockade: It is a non-selective inhibitor of Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2).
Prostaglandin Suppression: It prevents the conversion of arachidonic acid into Prostaglandins, which are the chemical messengers that sensitize pain receptors (nociceptors).
Peripheral Action: Unlike opioids, which work on the brain/CNS, Ketorolac stops the pain signal at the site of injury or surgery.
Tromethamine Salt: The “Tromethamine” part of the molecule is a buffer that technically increases the drug’s solubility and ensures rapid absorption into the bloodstream.
The Pharmacist’s “Technical Warning”
The “5-Day Rule”: As a pharmacist, I must emphasize that Ketorolac is not for chronic pain. Use beyond 5 days is technically linked to a massive increase in the risk of Gastrointestinal Bleeding and Acute Renal Failure.
The “Platelet” Warning: Ketorolac inhibits platelet aggregation. It must be used with extreme caution in post-operative patients where surgical bleeding (hemostasis) is a concern.
IV vs. IM: It can be given via Intramuscular (IM) or Intravenous (IV) bolus. When given IV, it should be administered over at least 15 seconds to avoid local vein irritation.
The “NSAID Ceiling”: Giving Ketorolac with other NSAIDs (like Ibuprofen or Naproxen) provides no extra pain relief but technically doubles the risk of stomach ulcers.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Stability” USP: Ketorolac is sensitive to Light and Oxygen. On your digital marketplace, highlight your Nitrogen-Purged Amber Ampoules. This is a technical requirement to prevent the solution from turning yellow-brown and losing potency (USP limit is usually 90–110%).
The “Opioid Alternative” Market: In 2026, the global B2B market is shifting toward “Multi-Modal Analgesia.” Market Ketorolac as a “Narcotic-Sparing Essential” to international surgical centers looking to reduce opioid-related complications like nausea and constipation.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Ketorolac 30 mg/mL ampoules to support your registration in international B2B tenders for surgery and emergency care.